

Holista CollTech's (ASX:HCT) distribution partner places \$3.8M order for NatShield

ASX:HCT MCAP \$37.66M



Ashleigh Melanko
 Markets Reporter
 ashleigh.melanko@themarket Herald.com.au
 09 April 2020 11:03



Managing Director, Dr Rajen Manicka (Left)
 Sourced: Malay Mail

- Health Therapies, a distribution partner for Holista CollTech (HCT), has placed a \$3.8 million order for Holista's NatShield sanitiser
- Approximately 415,000 bottles of NatShield will be delivered across the United States in the coming months
- The sanitiser contains Path-Away, which cripples a virus' cell wall, causing bacteria to group together and destroy themselves within seconds
- Holista is also developing online capabilities for NatShield to reach a wider audience
- Company shares are up a steady 14.3 per cent on the market this morning and are trading for 16 cents each

Health Therapies, a distribution partner of Holista CollTech (HCT), has placed a \$3.8 million order for Holista's NatShield sanitiser.

In [March](#), Holista appointed Health Therapies as its exclusive U.S. distributor for a three-year period. Health Therapies must spend at least \$3 million per year.

Following the success of two previous shipments from Malaysia, approximately 415,000 bottles will be delivered across the United States throughout the coming months.

Approximately 15,000 bottles will be shipped in April, while the remaining 400,000 will be shipped throughout May and June.

This increased order comes from strong demand from Health Therapies and U.S. State Administration, particularly in New York, where more than 6000 people have lost their lives.

Given that most of North America is in lockdown, Holista has recruited independent bottling companies to help with production. These companies span across Florida, South Carolina, and Georgia.

Holista's NatShield sanitisers contain Path-Away, which is a plant-based, active ingredient.

Path-Away works by crippling a virus' cell walls, causing bacteria to group together and destroy themselves within seconds.

In [March](#), Holista began testing Path-Away and its effectiveness against COVID-19. It will also be tested against other members of the coronavirus family, such as SARS (severe acute respiratory syndrome) and the more common influenza virus.

Testing is expected to be completed by the middle of this month, and results are expected within two to three weeks.

Holista is also developing its online capabilities in a bid to help its NatShield sanitiser reach a wider audience.

Company shares are up a steady 14.3 per cent on the market this morning and are trading for 16 cents each at 10:28 am AEST.